Announcement dated 7.08.2025 and pursuant to the approval of the Members of the Company dated 3rd September, 2025 and in accordance with Reg 30 and other applicable provisions of the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts less than Nifty Microcap 250 and 0.2 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shree Pacetronix Ltd has allotted 75,150 equity shares at Rs. 81 per share (including Rs. 71 premium), aggregating to Rs. 60.87 lakh, on a preferential basis. Additionally, the company has allotted 2,25,450 fully convertible equity warrants at an exercise price of Rs. 81 each, with 25% subscription money (Rs. 45.65 lakh) received upfront. All securities have been allotted to Akash Sethi, a promoter, who will hold 8.03% post-allotment (assuming full conversion of warrants) compared to 0.35% pre-issue. The warrants are split into Series A (convertible within 9 months) and Series B (convertible between 9-18 months), and the securities are subject to SEBI ICDR lock-in restrictions.
This preferential allotment to the promoter strengthens promoter shareholding from 0.35% to 8.03% and brings in additional capital, though the warrants may lead to further equity dilution upon conversion within 18 months. Existing shareholders should note the potential dilution risk from the convertible warrants.